Thermo Fisher Scientific (TMO) exhibits a resilient market performance despite a minor revenue dip. Its shares are acquired by Generate Investment Management Ltd. TMO recently introduced an integrated multimodal Analytical Scanning Transmission Electron Microscope for advancing materials research. Recent reports indicate an expected beat in earnings estimates and suggest it as a moderate buy. Investor confidence is high, with 113% return for those who invested five years ago. Bleakley Financial Group and B.O.S.S Retirement Advisors have reduced their shares while CX Institutional and Generate Investment Management have increased their holding. Barclays raised their TMO price target to $620.00. Q3 created anticipation among analysts expecting robust growth in the Analytical Instrument segment. The Greenville plant reportedly observed an insider sale due to probable manufacturing lapses. The firm hosted an investor day while expecting a drop-in earnings. However, it outpaced earnings growth with a five-year CAGR of 14%. Competition regulator cleared the $3.1 billion TMO-Olink deal. Its Q2 results showed marginal revenue dip but the firm completed the Olink acquisition and uplifted the annual profit outlook. Hedge fund holders were attracted due to robust fundamentals and TMO exceeded market returns.
Thermo Fisher Scientific TMO News Analytics from Wed, 06 Mar 2024 08:00:00 GMT to Sat, 19 Oct 2024 11:53:25 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor 4
